Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 4/20 | 0.67 |
| ▸ | ACHE | P22303 | 8/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9324677 | 0.85 | METAP1 (0.63) | METAP1ACHECYP19A1HTR1ADRD2 | |
| SCHEMBL16377312 | 0.82 | S100A4 (0.55) | METAP1ACHECYP19A1HTR2B | |
| SCHEMBL1853465 | 0.82 | ACHE (0.63) | METAP1ACHECYP19A1HTR1ADRD2 | |
| SCHEMBL5608451 | 0.81 | CYP19A1 (0.59) | METAP1ACHECYP19A1HTR1AHTR2C | |
| SCHEMBL6528990 | 0.81 | ACHE (0.62) | METAP1ACHECYP19A1HTR1ADRD2 | |
| SCHEMBL1705992 | 0.81 | METAP1 (0.62) | METAP1ACHECYP19A1HTR1ADRD2 | |
| SCHEMBL15617634 | 0.81 | METAP1 (0.62) | METAP1ACHECYP19A1HTR1ADRD2 | |
| SCHEMBL2175676 | 0.80 | METAP1 (1.00) | METAP1ACHECYP19A1 | |
| SCHEMBL8556555 | 0.80 | ACHE (0.60) | METAP1ACHECYP19A1HTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL2124625 | 0.79 | METAP1 (1.00) | METAP1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701684-B2 | Chiral fluorinating reagents | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| US-20150284401-A1 | CHIRAL FLUORINATING REAGENTS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2015-10-08 | — | — | US | disclosed |
| US-9040559-B2 | BETA2-adrenoceptor agonists | NOVARTIS AG (CH) | 2015-05-26 | — | — | US | disclosed |
| US-20140343091-A1 | BETA2-ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2014-11-20 | — | — | US | disclosed |
| US-8796307-B2 | Beta2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2014-08-05 | — | — | US | disclosed |
| WO-2014068341-A2 | CHIRAL FLUORINATING REAGENTS | ISIS INNOVATION LIMITED (GB) | 2014-05-08 | — | — | WO | disclosed |
| US-20140066478-A1 | Beta2-Adrenoreceptor Agonists | NOVARTIS AG (CH) | 2014-03-06 | — | — | US | disclosed |
| US-8658673-B2 | BETA2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2014-02-25 | — | — | US | disclosed |
| US-20130231367-A1 | BETA2-ADRENORECEPTOR AGONISTS | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| US-8436017-B2 | Beta-2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2013-05-07 | — | — | US | disclosed |
| EP-1446387-B1 | SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN CO LLC (US) | 2009-11-04 | — | — | EP | disclosed |
| EP-1183240-B1 | BETA2-ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-20050153957-A1 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | NOVARTIS AG (CH) | 2005-07-14 | — | — | US | disclosed |
| US-6878721-B1 | N-(partially hydrogenated fused carbocycle)-2-arylethylamine derivatives, e.g., 8-hydroxy-5-(1-hydroxy-2-(indan-2-ylamino)-ethyl)-1H-quinolin-2-one; treatment of obstructive or inflammatory | NOVARTIS AG (CH) | 2005-04-12 | — | — | US | disclosed |
| CN-1156451-C | Betz 2-adrenoceptor agonists | ��˹��ŵ�� | 2004-07-07 | — | — | CN | disclosed |
| US-6699909-B1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS; CENTRAL NERVOUS SYSTEM DISORDERS | PRESCIENT NEUROPHARMA INC. (CA) | 2004-03-02 | — | — | US | disclosed |
| CN-1353692-A | Betz 2-adrenoceptor agonists | NOVARTIS AG (CH) | 2002-06-12 | — | — | CN | disclosed |
| EP-1183240-A1 | BETA2-ADRENOCEPTOR AGONISTS | Novartis AG (CH) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000075114-A1 | BETA2-ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2000-12-14 | — | — | WO | disclosed |
| US-4166131-A | ANTIINFLAMMATORY AGENTS, ANTIPYRETICS, ANTIARTHRITIC AGENT | HEXACHIMIE SOCIETE ANONYME (FR) | 1979-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284401-A1 | CHIRAL FLUORINATING REAGENTS | TIAM1, AFF2, AFF1 | METAP1 3883/4885ACHE 3151/4885CYP19A1 551/4885 |
| US-20140066478-A1 | Beta2-Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | METAP1 3154/4885ACHE 1594/4885CYP19A1 2489/4885 |
| US-20140343091-A1 | BETA2-ADRENOCEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | METAP1 3893/4885ACHE 1206/4885CYP19A1 2798/4885 |
| US-20050153957-A1 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | ADRB3, ADRB2, ADRB1 | METAP1 2310/4885ACHE 346/4885CYP19A1 1785/4885 |
| US-20130231367-A1 | BETA2-ADRENORECEPTOR AGONISTS | ADRB2, ADRB1, ADRB3 | METAP1 2932/4885ACHE 1648/4885CYP19A1 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.